Last reviewed · How we verify
Saline solution, 0.6%
Hypotonic saline solution (0.6%) reduces corneal edema and improves corneal clarity by osmotically drawing fluid from swollen corneal tissue.
Hypotonic saline solution (0.6%) reduces corneal edema and improves corneal clarity by osmotically drawing fluid from swollen corneal tissue. Used for Corneal edema (Fuchs' endothelial dystrophy and other causes).
At a glance
| Generic name | Saline solution, 0.6% |
|---|---|
| Sponsor | Novaliq GmbH |
| Drug class | Osmotic agent / Ophthalmic decongestant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
The 0.6% saline solution is hypertonic relative to corneal tissue, creating an osmotic gradient that draws excess fluid out of edematous cornea. This reduces corneal swelling and improves transparency, restoring vision in patients with corneal edema. The mechanism is purely osmotic and does not involve receptor binding or enzymatic activity.
Approved indications
- Corneal edema (Fuchs' endothelial dystrophy and other causes)
Common side effects
- Ocular irritation
- Stinging or burning sensation
- Temporary blurred vision
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- Effects of Different Drugs for Glottic Atomization on Postoperative Sore Throat After Thyroid Surgery (PHASE4)
- Dexmedotomidine for Acute Pain Control in Patients With Multiple Rib FracturesRandomized Controlled Trial (PHASE4)
- Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (PHASE2)
- Hyalouronic Acid and Periodontal Surgery (NA)
- Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants (PHASE1)
- Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali (PHASE1, PHASE2)
- Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saline solution, 0.6% CI brief — competitive landscape report
- Saline solution, 0.6% updates RSS · CI watch RSS
- Novaliq GmbH portfolio CI